Microsphere-Based Immunoglobulin Subclass Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining immunoglobulin subclasses and isotypes in transplant candidates and patients with autoimmune diseases or allergies lack sensitivity and specificity, leading to inaccurate prognosis and diagnosis, particularly in predicting transplant outcomes and identifying antibodies that fix human complement.
Innovation Solution
A method involving the use of microspheres coated with MHC antigens, which are analyzed with monoclonal antibodies and detectably-labeled antibodies to quantify IgG1, IgG2, IgG3, and IgG4 subclasses in body fluids, providing a precise indication of transplant suitability and autoimmune disease or allergy diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to determine immunoglobulin subclasses and isotypes, then the analysis can be performed, but the sensitivity and specificity are insufficient leading to inaccurate prognosis and diagnosis
Solution Approach 1:
The patent introduces a two-step detection system using first and second detectably-labeled antibodies as intermediaries. The first antibody detects the immunoglobulin subclass/isotype, while the second antibody provides signal amplification. This intermediary approach significantly enhances measurement precision and reliability compared to conventional single-antibody methods.
Solution Approach 2:
The patent employs multiple detectable labels with different detection parameters (fluorescence, colorimetric, radioactive, magnetic properties). By changing the detection parameter and using signal amplification through sequential antibody binding, the method achieves higher sensitivity and specificity in immunoglobulin subclass analysis.
2Measurement precision
If conventional analysis methods are used, then the procedure is simpler, but the ability to accurately identify antibodies that fix human complement is reduced
Solution Approach 1:
The patent uses detectably-labeled antibodies as intermediaries to specifically identify complement-fixing antibody subclasses. The first detectably-labeled antibody binds to the immunoglobulin subclass, and the second detectably-labeled antibody provides additional signal amplification. This intermediary system enables precise identification of complement-fixing antibodies despite increased procedural complexity.
Solution Approach 2:
The patent employs detectable labels with various detection parameters (fluorescence intensity, colorimetric signals, radioactive decay, magnetic resonance) to enhance the detection capability for complement-fixing antibodies. By changing and amplifying the detection signal parameter, the method achieves superior precision in identifying these critical antibodies.
3Loss of information
If detailed analysis of all immunoglobulin subclasses is performed, then comprehensive diagnostic information is obtained, but the time and resources required increase
Solution Approach 1:
The patent combines multiple detection capabilities into a single assay system. By using detectably-labeled antibodies that can simultaneously or sequentially detect different immunoglobulin subclasses (IgG1, IgG2, IgG3, IgG4) and isotypes (IgM, IgA, IgE, IgD) in one sample, the method retrieves comprehensive diagnostic information efficiently without requiring separate tests for each subclass.
Solution Approach 2:
The detection system is designed with universal applicability to detect multiple immunoglobulin subclasses and isotypes using the same basic assay platform. The detectably-labeled antibodies can be configured to detect various subclasses simultaneously, making the system multi-functional and reducing the overall time and resources needed compared to performing separate specialized tests.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the sensitivity and specificity of immunoglobulin subclass analysis, correlating subclass distributions with clinical outcomes, enabling more accurate prognosis and diagnosis in transplant candidates and patients with autoimmune diseases or allergies.
Implementation Method 1
microspheres coated with MHC antigens, which are analyzed with monoclonal antibodies and detectably-labeled antibodies to quantify IgG1, IgG2, IgG3, and IgG4 subclasses
Data Source
AI summary
Methods and kits are provided for determining of immunoglobulin isotypes and subclasses in a subject. In general the subject is a human who is a transplant candidate recipient or recipient, has allergies, or has an autoimmune disease. The method involves analyzing a sample of a body fluid of a transplant candidate or recipient, allergy patient or autoimmune disease sufferer and correlating the relative amounts of each immunoglobulin isotype and subtype, such that the distribution of isotypes and subtypes is an indication of success of the transplant in the candidate and recipient or the prognosis of the autoimmune disease.